Weber, J. S., & Hassel, J. C. (2015). Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. The lancet. Oncology, 16(4), . https://doi.org/10.1016/S1470-2045(15)70076-8
Chicago-Zitierstil (17. Ausg.)Weber, Jeffrey S., und Jessica C. Hassel. "Nivolumab Versus Chemotherapy in Patients with Advanced Melanoma Who Progressed After Anti-CTLA-4 Treatment (CheckMate 037): A Randomised, Controlled, Open-label, Phase 3 Trial." The Lancet. Oncology 16, no. 4 (2015). https://doi.org/10.1016/S1470-2045(15)70076-8.
MLA-Zitierstil (9. Ausg.)Weber, Jeffrey S., und Jessica C. Hassel. "Nivolumab Versus Chemotherapy in Patients with Advanced Melanoma Who Progressed After Anti-CTLA-4 Treatment (CheckMate 037): A Randomised, Controlled, Open-label, Phase 3 Trial." The Lancet. Oncology, vol. 16, no. 4, 2015, https://doi.org/10.1016/S1470-2045(15)70076-8.